Leadership Overview
Eisai has 6 executives leading key functions including strategy, operations, scientific research, machinery, partnership management, and general management.
Driven by a commitment to patient well-being, Eisai focuses on developing innovative pharmaceutical products to address unmet medical needs, particularly in neurology and oncology, aiming to improve global health outcomes.
Driven by a commitment to patient well-being, Eisai focuses on developing innovative pharmaceutical products to address unmet medical needs, particularly in neurology and oncology, aiming to improve global health outcomes.
Leadership Roles at Eisai
Toshio Imai - President & Chief Executive Officer & Scientific Chief & Officer
Toshio Imai, the President & Chief Executive Officer & Scientific Chief & Officer at Eisai, directs the overarching corporate strategy and scientific vision. This leadership role encompasses guiding the company's pharmaceutical research and development efforts, ensuring alignment with global health needs and market opportunities. Imai oversees the advancement of key therapeutic areas, including Alzheimer's disease, dementia with Lewy bodies, epilepsy, and oncology, driving the progression of innovative treatments from discovery through to market. The executive's mandate includes fostering a culture of scientific excellence and rigorous clinical evaluation across all research divisions. By championing groundbreaking scientific initiatives, Toshio Imai ensures Eisai remains at the forefront of pharmaceutical innovation, delivering critical medicines to patients worldwide and solidifying the company's position in the global healthcare landscape.
Shaji Procida - President & Chief Operating Officer
Shaji Procida, the President & Chief Operating Officer at Eisai, executes the operational framework that supports the company's global pharmaceutical business. This executive directs the day-to-day functions critical to Eisai's product lifecycle, from manufacturing and supply chain management to commercial operations and market access. Procida ensures efficient resource allocation and operational excellence across all business units, facilitating the seamless delivery of vital medications like Aricept, Methycobal, and Fycompa to patients. The role involves optimizing internal processes and driving cross-functional collaboration to enhance productivity and responsiveness to market demands. By managing the intricate operational complexities, Shaji Procida underpins the company's ability to scale its impact and reliably serve diverse patient populations across various therapeutic areas, including pain management and insomnia treatments.
Michael De - President, Eisai Machinery (USA)
Michael De, the President, Eisai Machinery (USA) at Eisai, leads the specialized division focused on advanced manufacturing equipment and solutions. This executive directs the strategic development, production, and distribution of high-precision machinery essential for pharmaceutical manufacturing processes. De oversees operations within the United States, ensuring that Eisai Machinery provides state-of-the-art equipment that meets the stringent quality and efficiency demands of the pharmaceutical industry. The role involves driving technological innovation in machinery design and supporting clients with integrated solutions that enhance production capabilities. By managing this critical segment, Michael De ensures the operational backbone for pharmaceutical production is robust and technologically advanced, supporting Eisai's broader mission of delivering essential medicines.
Shawn Gallagher - President, Partnership Management Core Functional Unit
Shawn Gallagher, the President, Partnership Management Core Functional Unit at Eisai, orchestrates strategic alliances and collaborations vital for expanding the company's global reach and therapeutic portfolio. This executive directs the identification, negotiation, and management of key partnerships with external organizations, research institutions, and other pharmaceutical companies. Gallagher's responsibilities include fostering synergistic relationships that accelerate drug development, enhance market access, and drive innovation across Eisai's core therapeutic areas. The focus is on building mutually beneficial collaborations that leverage shared expertise and resources to bring novel treatments to patients more effectively. By cultivating these strategic relationships, Shawn Gallagher significantly contributes to Eisai's growth and its ability to address complex health challenges worldwide.
Jonnahs Singian - President & General Manager
Jonnahs Singian, the President & General Manager at Eisai, oversees the comprehensive business operations and strategic direction for a designated region or business unit. This executive is responsible for driving growth, ensuring operational efficiency, and maintaining market leadership within their purview. Singian manages all facets of the business, from commercial activities and product launches to financial performance and regulatory compliance. The role involves leading cross-functional teams to achieve ambitious corporate objectives and uphold Eisai's commitment to patient well-being. By providing decisive leadership and strategic oversight, Jonnahs Singian ensures the effective execution of Eisai's mission, contributing to the company's overall success in delivering innovative pharmaceutical solutions and improving patient outcomes.
Kenichi Nomoto - Chief Scientific Officer
Kenichi Nomoto, the Chief Scientific Officer at Eisai, spearheads the company's advanced scientific research and discovery initiatives. This critical role involves charting the course for novel therapeutic development, with a particular emphasis on groundbreaking treatments for neurological disorders and cancer. Nomoto directs the exploration of new scientific frontiers, identifying promising drug candidates and overseeing their preclinical evaluation. The executive's focus extends to fostering innovation within Eisai's research laboratories, ensuring the rigorous scientific validation of potential new medicines. By driving cutting-edge research, Kenichi Nomoto plays a pivotal part in expanding Eisai's pipeline of innovative pharmaceuticals, including agents for thyroid cancer, renal cell carcinoma, and breast cancer, thereby contributing significantly to the company's mission of improving patient lives through scientific advancement.
Explore Leadership Teams in Manufacturing
Lonza is a global supplier serving the pharmaceutical, biotech, and specialty ingredients markets. The company provides a broad portfolio of services and products, including active pharmaceutical ingredients, drinking water sanitizers, nutritional and personal care ingredients, agricultural solutions, industrial preservatives, and microbial control technologies that address harmful viruses, bacteria, and other pathogens. Founded in the Swiss Alps, Lonza operates through two primary market-focused segments — Pharma & Biotech and Specialty Ingredients — reflecting its commitment to innovation and global health advancement.
Company Leadership JO
RW
MM
Founded in 1850 and headquartered in Johannesburg, South Africa, Aspen Pharmacare Holdings Limited is a global specialty and branded pharmaceutical company headquartered in Durban, South Africa. Operating across Africa, the Middle East, the Americas, Europe CIS, Australasia, and Asia, Aspen focuses on sterile injectables (including anaesthetics, anticoagulants, antithrombotics, analgesics, and hormone replacement therapies), over-the-counter medicines, and prescription products for conditions such as hypothyroidism, autoimmune disease, pain, gout, and inflammatory disorders. The company also manufactures active pharmaceutical ingredients and finished dose forms, including steriles, oral solids, liquids, semi-solids, biologicals, and heparins, supplying both its own brands and third-party customers worldwide.
Company Leadership
TS
JW
Dong-A Socio Group is a professional healthcare organization that focuses on fulfilling social responsibility through various sectors including medical and digital healthcare, consumer products, logistics, IT services, and engineering. The company aims to enhance human health and well-being by providing specialized medical services, health functional foods, and integrated logistics solutions. With a commitment to innovation and consumer-oriented management, Dong-A Socio Group strives to create value and lead change in the industry. Their target clients include healthcare providers, consumers seeking health products, and businesses requiring logistics and IT solutions.
Company Leadership HH
WK
SP
CK
ImmunityBio is a vertically-integrated biotechnology company developing next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. The Companys range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease. Designated an FDA Breakthrough Therapy, ANKTIVA is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer CIS that activates natural killer cells, T cells, and memory T cells for a long-duration response. The Company is applying its science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that we believe sharply reduce or eliminate the need for standard high-dose chemotherapy. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases.
Company Leadership FJ
Frequently Asked Questions Regarding Eisai Top Executives and Leadership Team
